ArticleDiscover oncology2025
Upregulation of EMP3 in acute myeloid leukemia: a study based on data mining, RT-qPCR and immunohistochemistry.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEpithelial Membrane Protein 3 (EMP3) has been associated with multiple malignancies, but its expression patterns and clinical significance in acute myeloid leukemia (AML) remain poorly characterized.
methodsPublic datasets were integrated to assess EMP3 mRNA expression levels in AML patients versus healthy donors, with validation performed using reverse transcription quantitative PCR (RT-qPCR). Protein expression was accessed through immunohistochemistry. Prognosis relevance was evaluated via survival analysis. Molecular mechanisms were investigated using weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, immune infiltration assessment, and pathway enrichment analysis.
resultsElevated EMP3 expression was detected in AML samples relative to healthy donors, showing a standardized mean difference (SMD) of 0.84 (95% CI: 0.63, 1.05). This upregulation was validated by RT-qPCR and immunohistochemical analyses, yielding a consistent SMD of 0.94 (95% CI: 0.57, 1.32) when RT-qPCR data were included. Prognostic assessment indicated a significant association between EMP3 levels and AML clinical outcomes. Among 829 genes co-expressed with EMP3, enrichment was observed in acute myeloid leukemia-related pathways, with BCL2A1 and ITGAM identified as hub co-expressed genes.
conclusionThese findings suggest that EMP3 overexpression occurs in AML and potentially influences disease prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.